{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:28:15Z","timestamp":1787923695116,"version":"build-2784847793"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the antimicrobial activity of ceftaroline and comparator antimicrobials against clinical isolates of Gram-positive bacteria (GPB) from paediatric patients globally and in Africa\/Middle East (AfME), Asia\u2013Pacific (APAC), Europe and Latin America (LATAM) as part of the Antimicrobial Testing Leadership and Surveillance programme between 2018 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Susceptibility and minimum inhibitory concentrations of all organisms were determined using broth microdilution methodology for ceftaroline and comparators from Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall and across regions, Staphylococcus aureus (CLSI\/EUCAST, \u226599.0%) and methicillin-resistant S. aureus (CLSI, \u226595.6%) demonstrated high susceptibility to ceftaroline. High susceptibility to daptomycin, linezolid, teicoplanin, tigecycline (from the FDA), trimethoprim\/sulfamethoxazole and vancomycin was demonstrated against these isolates for both breakpoints. Globally and across regions, for Streptococcus pneumoniae (CLSI\/EUCAST, 93.3%\u2013100%) and penicillin-intermediate S. pneumoniae (CLSI\/EUCAST, 100%), high susceptibility to ceftaroline was observed. For penicillin-resistant S. pneumoniae, higher susceptibility to ceftaroline following the CLSI (96.5%\u2013100%) than EUCAST (74.4%\u201388.7%) was observed except in LATAM. High susceptibility to linezolid, levofloxacin, tigecycline and vancomycin was demonstrated against these isolates across regions from both breakpoints, whereas, for ceftriaxone, higher susceptibility following the CLSI than EUCAST was observed. For \u03b2-haemolytic streptococci, high susceptibility to ceftaroline was observed (CLSI, 100%). High susceptibility to linezolid, penicillin and vancomycin was demonstrated against these isolates from both breakpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ceftaroline demonstrated potent activity against key GPB. This study significantly contributes to the limited current information on paediatric antimicrobial resistance patterns across AfME, APAC, Europe and LATAM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag179","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:39:23Z","timestamp":1786448363000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>In vitro<\/i>\n                    activity of ceftaroline against clinical isolates of Gram-positive bacteria in paediatric patients: ATLAS programme 2018\u20132023"],"prefix":"10.1093","volume":"8","author":[{"given":"Pattarachai","family":"Kiratisin","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok 10700 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Kuraieva","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , 66 Hudson Blvd E., New York, NY 10001 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Utt","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Groton, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma , Parma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026082805042024700_dlag179-B1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics12020261","article-title":"Therapeutic options and outcomes for the treatment of children with Gram-positive bacteria with resistances of concern: a systematic review","volume":"12","author":"Chiusaroli","year":"2023","journal-title":"Antibiotics"},{"key":"2026082805042024700_dlag179-B2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1515\/med-2022-0440","article-title":"Linezolid for resistant gram-positive bacterial infections in children under 12 years: a meta-analysis","volume":"17","author":"Wu","year":"2022","journal-title":"Open Med (Wars)"},{"key":"2026082805042024700_dlag179-B3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/antibiotics10040393","article-title":"Antibiotic resistance in pediatric infections: global emerging threats, predicting the near future","volume":"10","author":"Romandini","year":"2021","journal-title":"Antibiotics"},{"key":"2026082805042024700_dlag179-B4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/ph16091304","article-title":"New antimicrobials for Gram-positive sustained infections: a comprehensive guide for clinicians","volume":"16","author":"Carcione","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026082805042024700_dlag179-B5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2352-4642(25)00162-2","article-title":"Advances and challenges in childhood pneumonia","volume":"9","author":"The Lancet Child Adolescent Health","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"2026082805042024700_dlag179-B6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12887-025-05825-z","article-title":"Epidemiological trends and disparities in the global burden of bacterial skin diseases among children and adolescents from 1990 to 2021: an analysis based on GBD 2021","volume":"25","author":"Guo","year":"2025","journal-title":"BMC Pediatr"},{"key":"2026082805042024700_dlag179-B7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad296","article-title":"Staphylococcus aureus bacteremia in pediatric patients: uncovering a rural health challenge","volume":"10","author":"Whittington","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026082805042024700_dlag179-B8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026082805042024700_dlag179-B9","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1007\/s00431-024-05672-7","article-title":"The prevalence and risk factors of methicillin-resistant Staphylococcus aureus among pediatric populations: a systematic review and meta-analysis","volume":"183","author":"Al-Iede","year":"2024","journal-title":"Eur J Pediatr"},{"key":"2026082805042024700_dlag179-B10","volume-title":"WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance","author":"WHO","year":"2024"},{"key":"2026082805042024700_dlag179-B11","doi-asserted-by":"publisher","first-page":"101458","DOI":"10.1016\/j.eclinm.2022.101458","article-title":"The global burden of sore throat and group A Streptococcus pharyngitis: a systematic review and meta-analysis","volume":"48","author":"Miller","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026082805042024700_dlag179-B12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00431-022-04718-y","article-title":"Group A streptococcal disease in paediatric inpatients: a European perspective","volume":"182","author":"Boeddha","year":"2023","journal-title":"Eur J Pediatr"},{"key":"2026082805042024700_dlag179-B13","doi-asserted-by":"publisher","first-page":"S1305","DOI":"10.1016\/j.ajog.2022.07.051","article-title":"Group B Streptococcus and the risk of perinatal morbidity and mortality following term labor","volume":"228","author":"Stephens","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2026082805042024700_dlag179-B14","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2214-109X(22)00093-6","article-title":"Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden","volume":"10","author":"Gon\u00e7alves","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026082805042024700_dlag179-B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40121-013-0010-x","article-title":"Ceftaroline fosamil: a brief clinical review","volume":"2","author":"Shirley","year":"2013","journal-title":"Infect Dis Ther"},{"key":"2026082805042024700_dlag179-B16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"key":"2026082805042024700_dlag179-B17"},{"key":"2026082805042024700_dlag179-B18"},{"key":"2026082805042024700_dlag179-B19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/IDR.S423004","article-title":"In vitro activity of ceftaroline against isolates of Gram-positive bacteria from patients with bloodstream infections collected as a part of ATLAS between 2017 and 2020","volume":"17","author":"Kempf","year":"2024","journal-title":"Infect Drug Resist"},{"key":"2026082805042024700_dlag179-B20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime\u2013avibactam: a surveillance study from the ATLAS program (2012\u20132016)","volume":"9","author":"Zhang","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026082805042024700_dlag179-B21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40272-021-00468-w","article-title":"Ceftaroline fosamil for treatment of pediatric complicated skin and soft tissue infections and community-acquired pneumonia","volume":"23","author":"Esposito","year":"2021","journal-title":"Paediatr Drugs"},{"key":"2026082805042024700_dlag179-B22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jgar.2023.05.002","article-title":"Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017\u20132019","volume":"33","author":"Utt","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2026082805042024700_dlag179-B23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/INF.0000000000001477","article-title":"Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in paediatric patients from United States hospitals: 2012\u20132014","volume":"36","author":"Pfaller","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 3","key":"2026082805042024700_dlag179-B24","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1093\/cid\/cis560","article-title":"Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE ceftaroline surveillance program","volume":"55","author":"Sader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026082805042024700_dlag179-B25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/INF.0000000000000307","article-title":"Ceftaroline activity tested against bacterial isolates from paediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012)","volume":"33","author":"Sader","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026082805042024700_dlag179-B26","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab159","article-title":"Evaluation of the in vitro activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012\u201319","volume":"3","author":"Al-Sweih","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026082805042024700_dlag179-B27","author":"ATLAS Surveillance"},{"key":"2026082805042024700_dlag179-B28","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing \u2014 Thirty-Fifth Edition: M100","author":"CLSI","year":"2025"},{"key":"2026082805042024700_dlag179-B29","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)."},{"key":"2026082805042024700_dlag179-B30","author":"Tygacil"},{"key":"2026082805042024700_dlag179-B31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40261-017-0523-2","article-title":"Current clinical trials on the use of ceftaroline in the pediatric population","volume":"37","author":"Corey","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2026082805042024700_dlag179-B32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jcpt.13316","article-title":"High-level ceftaroline resistance in a paediatric patient with invasive methicillin-resistant Staphylococcus aureus infection without previous ceftaroline exposure","volume":"46","author":"Ferguson","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2026082805042024700_dlag179-B33","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Ninth Edition: M100Ed29","author":"CLSI","year":"2019"},{"key":"2026082805042024700_dlag179-B34","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"key":"2026082805042024700_dlag179-B35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4314\/ejhs.v33i1.18","article-title":"Ceftaroline susceptibility among isolates of MRSA: a comparison of EUCAST and CLSI breakpoints","volume":"33","author":"Sachu","year":"2023","journal-title":"Ethiop J Health Sci"},{"key":"2026082805042024700_dlag179-B36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofag009","article-title":"Overcoming ceftaroline resistance in MRSA using ceftaroline-carbapenem combination therapy","volume":"13","author":"Olson","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"2026082805042024700_dlag179-B37","first-page":"293","article-title":"DTest method for detection of inducible clindamycin resistance in Staphylococcus aureus","volume":"19","author":"Sedighi","year":"2009","journal-title":"Iran J Pediatr"},{"key":"2026082805042024700_dlag179-B38","doi-asserted-by":"publisher","first-page":"114843","DOI":"10.1016\/j.diagmicrobio.2019.05.015","article-title":"Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015\u20132016","volume":"95","author":"Bae","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026082805042024700_dlag179-B39","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082805042024700_dlag179-B40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3389\/fmicb.2020.00797","article-title":"Emerging threat of antimicrobial resistance in \u03b2-hemolytic streptococci","volume":"11","author":"Oppegaard","year":"2020","journal-title":"Front Microbiol"},{"key":"2026082805042024700_dlag179-B41","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther"},{"key":"2026082805042024700_dlag179-B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jgar.2021.04.020","article-title":"In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections","volume":"26","author":"Pi\u00e9rard","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag179\/70826976\/dlag179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag179\/70826976\/dlag179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:45:16Z","timestamp":1787921116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag179\/8772267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag179","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag179"}}